Ex­clu­sive: Af­ter Am­gen ex­it, fa­ther-son duo gets Light­speed back­ing to fund re­main­ing Teneo­bio 'ba­bies'

The fa­ther-son duo be­hind Teneo­bio is back with an­oth­er biotech, com­pris­ing three bis­pe­cif­ic an­ti­bod­ies that nei­ther Am­gen want­ed when dish­ing out $900 mil­lion up­front last …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER